AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
Comes After Delay For Roxadustat In The US
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.
You may also be interested in...
Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.